Pgiam/iStock via Getty Images Goldman Sachs on Friday reviewed the generic drug industry, initiating the
Teva Pharmaceutical Industries (NYSE:TEVA) announced the pricing and early acceptance results of its previously announced
georgeclerk Truist Securities launched its coverage of Teva Pharmaceutical (NYSE:TEVA) with a Buy recommendation on
Teva Pharmaceutical Industries (NYSE:TEVA) on Tuesday said it has upsized its offering and priced about
alexsl Teva Pharmaceutical (NYSE:TEVA) was upgraded to Overweight from Neutral at J.P. Morgan on margin
Earnings Call Insights: Teva Pharmaceutical Industries Limited (TEVA) Q1 2025 Management View CEO Richard Francis
JHVEPhoto/iStock Editorial via Getty Images Shares of Teva Pharmaceutical (NYSE:TEVA) traded higher in the premarket
Teva Pharmaceutical press release (NYSE:TEVA): Q1 Non-GAAP EPS of $0.52. Revenue of $3.89B (+1.8% Y/Y).
Teva Pharmaceutical (NYSE:TEVA) is scheduled to announce Q1 earnings results on Wednesday, May 7th, before
undefined undefined/iStock via Getty Images The European Commission has withdrawn the regulatory authorization granted for